BioSpace News Archive

Takeda’s vedolizumab met its primary endpoint in the Phase III GRAPHITE study, significantly improving event-free survival in patients with acute graft-versus-host disease.

Hemab Therapeutics announced the closing of an oversubscribed Series B round to bring new treatment options for lesser-known bleeding disorders.

The FDA granted accelerated approval Friday to Travere Therapeutics’ sparsentan, now to be marketed as Filspari, to reduce the burden of proteinuria in adults with primary IgA nephropathy.

On Friday, the FDA approved Apellis Pharmaceuticals’ Syfovre (pegcetacoplan) as the first treatment for geographic atrophy (GA), a leading cause of blindness.

Immunovia AB, reg. no. 556730-4299, hereby gives notice that an Extraordinary General Meeting will take place on Thursday 16th March 2023 at 10.00 at The Spark, Scheeletorget 1, Medicon Village, in Lund.

Oxford Biomedica, a leading gene and cell therapy group, announces that Dr Frank Mathias will officially join Oxford Biomedica as Chief Executive Officer and Board member on Monday, 27th March 2023.

Mineralys Therapeutics, Inc. (Nasdaq: MLYS) announced today that abstracts featuring lorundrostat clinical data from both Phase 2 and Phase 1 studies have been selected for a moderated poster presentation and poster presentation at the American College of Cardiology’s 72nd Annual Scientific Session together with the World Congress of Cardiology (ACC.23/WCC).

The Diversity Now Protocol by RxE2 provides a pharmacist-centered approach for compliance with Section V, Categories 4 and 5 of the US Food and Drug Administration’s industry guidance (FDA Diversity Plans to Improve Enrollment of Participants from Underrepresented Racial and Ethnic Populations in Clinical Trials – Guidance for Industry, April 2022).

Delray Medical Center is the first hospital in Florida to treat an Alzheimer’s disease patient using non-invasive focused ultrasound technology as part of a groundbreaking study being conducted in collaboration with Florida Atlantic University’s Institute for Human Health and Disease Intervention (I-Health).

Eurofins Environment Testing Northern California: Wastewater (EWW) and Eurofins Pandemic Prevention Services (EPPS) today launched a droplet digital PCR (ddPCR) assay for the quantitative analysis of SARS-CoV-2 Variant of Concern (VoC) XBB.1.5 in wastewater.